

Gout hospitalization exacerbated by failure to prescribe recommended urate-lowering treatment

June 16 2017

The results of a Swedish study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 revealed an increasing incidence of hospitalisation due to gout over the last decade, with a resultant increase in health care costs. Also, worryingly, many of the patients admitted to hospital had not been receiving the recommended urate-lowering treatment (ULT).

A second study in the UK showed that nurse-provided patient education and support for a 'treat to target' management of gout resulted in a high uptake and excellent adherence to ULT over a 2-year period, with achievement of target serum uric acid (SUA) in more than 90% of cases, and consequent improvements in patient-centred outcomes and quality of life.

Increase in gout hospitalisation exacerbated by widespread failure to treat

From 2000 to 2012, the annual hospitalisation rate for gout in western Sweden increased from 12.2 to 16.7 per 100,000 adults (p=0.0038). This increase was most pronounced in males aged 65 and above, and over the last three years of the study. In addition, the length of hospitalisation increased from a median of 3 days to 5 days in 2000 and 2012 respectively (p=0.021).1



These findings are in marked contrast to the overall trend in hospitalisation across the Western Swedish Health Care Region (WSHCR). Over the same decade, the total amount of days for inpatient care due to physical conditions in WSHCR decreased by 9% from 2002 to 2012 (1,267,900 days, mean duration 5.7 days vs. 1,151,630 days, mean duration 4.9 days respectively).1

From 2009 to 2012, the inflation-adjusted health care costs for gout hospitalisations increased from USD 521,000 to USD 815,000. Only a minority of patients, 19 to 27%, received ULT in the 6 months preceding their hospitalisation, without any obvious cyclical or seasonal trend.1

"The incidence of hospitalisation for primary gout has increased substantially in Sweden over the last decade, and this is reflected in the associated health care costs," said lead author Dr. Mats Dehlin from Sahlgrenska Academy, University of Gothenburg, Sweden. "Although we would expect more hospitalisations due to the increasing incidence of gout among an aging population, the problem is being exacerbated by the fact that only one fourth of hospitalised patients were on the recommended ULT preceding their admission," he added.

Gout is the most common arthritic disease in the world, with an increasing incidence and prevalence. An increase in hospitalisation for gout has been shown over the last two decades in North America. "It is important to collect these data from different parts of the world as there will be variations in gout prevalence and the course of the disease, due to cultural, ethnic and genetic factors," Dr. Dehlin concluded.

Hospitalisation trends for gout were studied using data from the health care consumption register from 1st January 2001 through to 31st December 2012 in WSHCR, an area of the country believed to be representative of the whole of Sweden. Patients aged 18 years and older



who were hospitalised during the study period with a principal ICD-10 diagnosis of gout at discharge were included.

Annual population rates for hospitalisation for gout were calculated. Inflation-adjusted <u>health care costs</u> for the gout hospitalisations were calculated using the Cost-Per-Patient register. Dispensation of ULT, including allopurinol and probenecid, within 6 months prior to <u>hospitalisation</u>, was identified using The Swedish Prescribed Drug Register.

In total, there were 1,873 hospitalisations for gout (mean age 75.0-77.6 years, 61-74% men) between 2000 and 2012. Demographic characteristics were similar over the study period.

Nurse-led management of gout following treat to target principles significantly improves patient outcomes compared to standard general practitioner care

To directly compare nurse-led care to standard general practitioner (GP) care of people with gout, 517 participants with acute gout in the previous year, identified from 56 local GP practices, were randomised to receive either one or the other type of care in a 2-year controlled trial.

After receiving full information about gout almost all participants in the nurse-led group wanted ULT. Comparing the nurse and GP groups at 2 years: 95% vs. 29% achieved a target serum uric acid (SUA)

Citation: Gout hospitalization exacerbated by failure to prescribe recommended urate-lowering treatment (2017, June 16) retrieved 11 May 2024 from https://medicalxpress.com/news/2017-06-gout-hospitalization-exacerbated-failure-urate-



lowering.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.